Gilead Sciences, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 126   

Articles published

GILD 50.60 -1.34 (-2.58%)
price chart
Gilead Sciences, Inc. (GILD), American International Group, Inc. (AIG): The ...
The S&P 500 fell nearly 10% in June 2008, and investors began to brace for an eventual market crash later in the year. That was also a time when companies sealed the hatches and girded for tough days ahead, in many instances eliminating dividends that ...
Related articles »  
Gilead Sciences, Inc. (GILD): Three Key Advances in HIV Prevention
Gilead Sciences, Inc. (NASDAQ:GILD) In parallel with the development of more effective HIV treatments, researchers are also making tremendous progress in the prevention of this disease.
HIV drug can also protect injection drug users  KERO-TV 23
HIV drug discovery puts licensing pressure on govt  Bangkok Post
Related articles »  
GILEAD SCIENCES, INC. : Gilead Sciences to Present at the Wells Fargo ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the Wells Fargo Securities 2013 Healthcare Conference in Boston.
Related articles »  
Boeing Takes Over #37 Spot From Gilead Sciences
Below is a chart of Boeing Co. versus Gilead Sciences, Inc. plotting their respective size rank within the S&P 500 over time (BA plotted in blue; GILD plotted in green): Loading+chart+�+2013+TickerTech.
Oppenheimer Reiterates Outperform Rating for Gilead Sciences (GILD)  The Utah People's Post
Related articles »  
GILEAD SCIENCES, INC. : Gilead Announces Interim Phase 2 Data for Idelalisib ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced interim results from a single-arm, open-label Phase 2 study (Study 101-09) evaluating idelalisib (formerly GS-1101), an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of ...
Related articles »  
Biotech Most Active Stocks, MannKind Corporation, Cytokinetics, Gilead ...
Cytokinetics, Inc. (NASDAQ:CYTK) is planning to join Russell Global Index. Investment in Gilead Sciences, Inc. (NASDAQ:GILD) will be a clever move as its value got doubled.
Hedge Funds Are Betting On Gilead Sciences, Inc. (GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) was in 63 hedge funds' portfolio at the end of March. GILD shareholders have witnessed an increase in hedge fund sentiment of late.
Gilead Sciences, Inc. (GILD), Celgene Corporation (CELG): Thursday's Top ...
This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on.
Related articles »  
NASDAQ Active Stock Watch List: MannKind Corp. (NASDAQ:MNKD) and ...
Gilead Sciences Inc. (NASDAQ:GILD) a biopharmaceutical company that discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia is currently down (-0.67%) on 1,118,205 ...
Related articles »  
GILEAD SCIENCES, INC. : Companies Taking Strategic Initiatives in Delivering ...
Today, Wall Street Reports announced new research reports highlighting ResMed Inc. (NYSE: RMD), Quest Diagnostics Inc. (NYSE: DGX), Mettler-Toledo International, Inc. (NYSE: MTD), Gilead Sciences, Inc. (NASDAQ: GILD), and TearLab Corporation ...
Related articles »